This manuscript describes and discusses the molecular biology usage in CML patients as an advance in clinical practice using known biomarkers such BCR::ABL1 expression and ABL1 mutations. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.